BlackRock Virginia Municipal Bond Trust (BHV) At $16.75 Forms Bottom; Arqule (ARQL) Shorts Raised By 11.18%

June 30, 2018 - By rebbecca

ArQule, Inc. (NASDAQ:ARQL) Logo

BlackRock Virginia Municipal Bond Trust (BHV) formed multiple bottom with $15.91 target or 5.00% below today’s $16.75 share price. BlackRock Virginia Municipal Bond Trust (BHV) has $26.85M valuation. The stock decreased 0.18% or $0.0297 during the last trading session, reaching $16.7502. About 700 shares traded. BlackRock Virginia Municipal Bond Trust (NYSE:BHV) has risen 0.19% since June 30, 2017 and is uptrending. It has underperformed by 12.38% the S&P500.

Arqule Inc (NASDAQ:ARQL) had an increase of 11.18% in short interest. ARQL’s SI was 1.78M shares in June as released by FINRA. Its up 11.18% from 1.60 million shares previously. With 1.47M avg volume, 1 days are for Arqule Inc (NASDAQ:ARQL)’s short sellers to cover ARQL’s short positions. The SI to Arqule Inc’s float is 3.21%. The stock increased 9.72% or $0.49 during the last trading session, reaching $5.53. About 1.94 million shares traded or 10.74% up from the average. ArQule, Inc. (NASDAQ:ARQL) has risen 340.17% since June 30, 2017 and is uptrending. It has outperformed by 327.60% the S&P500. Some Historical ARQL News: 15/03/2018 – $ARQL ARQ 531 should also start getting more credit in next-gen BTKi race, esp after recent setback of $SNSS Initial Phase 1a data at #AACR18; 17/04/2018 – ARQULE – BASILEA WILL BE RESPONSIBLE FOR ALL COSTS AND EXPENSES OF DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION IN ITS TERRITORY; 10/05/2018 – Sphera Funds Buys New 2.6% Position in ArQule; 17/04/2018 – ARQULE – ALSO ENTITLED TO RECEIVE STAGGERED SINGLE-DIGIT TO DOUBLE-DIGIT ROYALTIES ON NET SALES UPON COMMERCIALIZATION; 17/04/2018 – ArQule May Have the Opportunity to Promote Derazantinib in the US Directly; 17/04/2018 – ARQULE – UNDER CERTAIN CIRCUMSTANCES, CO MAY HAVE OPPORTUNITY TO PROMOTE DERAZANTINIB IN U.S. DIRECTLY; 07/05/2018 – ArQule Sees 2018 Loss/Shr 18c-Loss 24c; 07/05/2018 – ARQULE INC – ARQULE EXPECTS TO END 2018 WITH BETWEEN $40 AND $42 MLN IN CASH AND MARKETABLE SECURITIES; 17/04/2018 – BASILEA PHARMACEUTICA AG BSLN.S – LICENSES LATE-STAGE ONCOLOGY DRUG CANDIDATE DERAZANTINIB FROM ARQULE; 15/03/2018 – ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting

Among 5 analysts covering Arqule (NASDAQ:ARQL), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arqule has $7.5 highest and $3.0 lowest target. $5.60’s average target is 1.27% above currents $5.53 stock price. Arqule had 6 analyst reports since February 2, 2018 according to SRatingsIntel. The rating was initiated by FBR Capital with “Buy” on Friday, February 2. On Thursday, April 5 the stock rating was upgraded by Leerink Swann to “Buy”. B. Riley & Co maintained ArQule, Inc. (NASDAQ:ARQL) rating on Monday, February 12. B. Riley & Co has “Buy” rating and $3.5 target. The rating was maintained by FBR Capital on Friday, June 29 with “Buy”. The stock has “Buy” rating by Oppenheimer on Monday, June 11.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company has market cap of $528.09 million. The Company’s lead product candidate is tivantinib , a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. It currently has negative earnings. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death.

More important recent ArQule, Inc. (NASDAQ:ARQL) news were published by: which released: “ArQule: Elucidating The Prospects Of An Interesting Grower” on June 21, 2018, also published article titled: “Oppenheimer Sees New Life In 22-Year-Old ArQule Stock”, published: “Key events next week – healthcare” on June 08, 2018. More interesting news about ArQule, Inc. (NASDAQ:ARQL) was released by: and their article: “ArQule (ARQL) PT Raised to $7.50 at B.Riley/FBR” with publication date: June 29, 2018.

ArQule, Inc. (NASDAQ:ARQL) Ratings Chart